WealthBridge Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

WealthBridge Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,706	Closed	-$81K	–	201
2019 Q1	$81K	Buy	1,706 +357	+26%	+$17.8K	0.05%	214
2018 Q4	$70K	Buy	+1,349	New	+$72.5K	0.05%	204

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WealthBridge Capital Management's BMY Position: Q2 2019 in Review

WealthBridge Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2019, closing a stake of 1,706 shares — an estimated $81K sold.

WealthBridge Capital Management first reported a position in BMY in Q4 2018 and held it in 2 quarters. The position peaked at $81K in Q1 2019. 1,777 funds tracked by Wall St. Rank hold BMY as of Q2 2019.

WealthBridge Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2019 after selling out during the quarter.
WealthBridge Capital Management sold 1,706 Bristol-Myers Squibb shares in Q2 2019, an estimated $81K.
WealthBridge Capital Management first reported a position in Bristol-Myers Squibb in Q4 2018 and held it in 2 quarters.
WealthBridge Capital Management's Bristol-Myers Squibb position peaked at $81K in Q1 2019.
1,777 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2019.

Based on WealthBridge Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.